These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21151038)

  • 1. Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema.
    Chhablani JK
    Eye (Lond); 2011 Feb; 25(2):254; author reply 254. PubMed ID: 21151038
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Parravano M; Menchini F; Virgili G
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Evans JR
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Brunetti M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?
    Biester S; Ziemssen F; Ulrich Bartz-Schmidt K; Gelisken F
    Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1575-7. PubMed ID: 19582472
    [No Abstract]   [Full Text] [Related]  

  • 8. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?
    Wickremasinghe S
    Clin Exp Ophthalmol; 2011; 39(7):595-7. PubMed ID: 22452678
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
    Kim HD; Kang KD; Choi KS; Rhee MR; Lee SJ
    Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-term response of macular oedema to intravitreal bevacizumab.
    Welch DE; Elmariah H; Peden MC; Adams SG; Ratnakaram R; Kaushal S
    Br J Ophthalmol; 2009 Aug; 93(8):1033-6. PubMed ID: 19403519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and retinal ischemia.
    Neubauer AS; Kook D; Haritoglou C; Priglinger SG; Kampik A; Ulbig MW; Ceklic L
    Ophthalmology; 2007 Nov; 114(11):2096. PubMed ID: 17980746
    [No Abstract]   [Full Text] [Related]  

  • 15. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR; Hosseini H
    Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-angiogenesis drugs in diabetic retinopathy.
    Jeganathan VS
    Curr Pharm Biotechnol; 2011 Mar; 12(3):369-72. PubMed ID: 20939797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antivascular endothelial growth factor in diabetic retinopathy.
    Iacono P; Battaglia Parodi M; Bandello F
    Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm.
    Chanana B; Azad RV
    Eye (Lond); 2009 Feb; 23(2):493-4. PubMed ID: 18388958
    [No Abstract]   [Full Text] [Related]  

  • 20. Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon.
    Ziemssen F; Spital G
    J Diabetes Complications; 2014; 28(2):119. PubMed ID: 24360342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.